Nathan Wong/LinkedIn
Mar 27, 2026, 16:23
Nathan Wong: Lp(a) Testing as a Class I Recommendation in 2026 Guidelines
Nathan Wong, Professor and Director of the Heart Disease Prevention Program, Division of Cardiology at UC Irvine, shared a post on LinkedIn:
“Today is Lp(a) Awareness Day and testing it at least once in all adults is now a Class I recommendation from the new 2026 ACC/AHA/Multisociety Dyslipidemia Guideline and there’s a lot we can do to lower risk in those with elevated levels.”
American College of Cardiology shared a post on LinkedIn:
“Learn about the unique role of Lp (a) as a genetic determinant for ASCVD risk and the importance of testing for Lp (a) levels to better understand your patients’ cardiovascular health with ACC’s online course.”
Stay updated with Hemostasis Today.
-
Nov 9, 2026, 13:48PF4-ELISA–Negative HIT: Are We Missing a New Class of Anti-PF4 Immunothrombotic Disease?
-
Nov 9, 2026, 13:07Nandini Sadasivam: Gene Therapy for Sickle Cell Disease and Thalassaemia
-
Nov 9, 2026, 13:04Raising Awareness of Bleeding Disorders in Women and Girls – EHC
-
Nov 9, 2026, 12:59Rahul Bohra: Exploring the Complex Mechanisms of Sickle Cell Disease
-
Nov 9, 2026, 12:53Three Years of Movement and Thrombosis Awareness in the Czech Republic – World Thrombosis day
-
Nov 9, 2026, 12:51Octavio Marques Pontes-Neto: Intensive Blood-Pressure Control Reduces Cardiovascular Events After Ischemic Stroke
-
Nov 9, 2026, 12:49Irma Bagdoniene: What Really Makes Us Live Longer
-
Nov 9, 2026, 12:47Imo Akpan: Announcing the 2027 Women’s Hematology Summit
-
Nov 9, 2026, 12:45Shadi Yaghi: Rethinking Antithrombotic Therapy After Stroke